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To identify patients with severe chronic heart failure who
are at greatest risk of developing functional renal in-
sufficiency during converting enzyme inhibition, creat-
inine clearance was measured in 59 patients before and
after long-term therapy with captopril (39 patients) or
enalapril (20 patient s), while digitalis and diuretic ther -
apy was kept constant. Creatinine clearance increased
or remained constant in 33 of the 59 patients (Group I) ,
but declined in the remaining 26 patients (Group II).
The two groups were similar with respect to the cause
of heart failure, pretreatment renal function and all pre-
treatment hemodynamic variables. Patients in Group II ,
however , had lower values for serum sodium concen-
tration (134.8 ± 1.0 versus 137.0 ± 0.6 mmol/liter ) and
higher values for plasma renin activity (10.6 ± 3.4 ver-
sus 3.0 ± 0.5 ng/ml per hour ), received larger doses of
furosemide (108 ± 11 versus 84 ± 6 mg/day), were more
frequently diabetic (42 versus 15%) and were more fre-
quently treated with enalapril (50 versus 21%) than were
patients in Group I (all p < 0.05). By stepwise logistic
analysis, only hyponatremia (or an elevated plasma renin
Although inhibition of the angiotensin converting enzyme
is of es tab lished value in the management of seve re chronic
heart failure ( 1,2), this therapeutic approach is co mmonly
acco mpa nied by systemic hypotension and function al renal
insufficiency. which may limit the utility of treatment in
some patient s (3,4) . These two adverse effec ts are the ex-
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activity) and enalapril therapy independently predicted
the decline in creatinine clearance during converting en-
zyme inhibition. These observations could not be ex-
plained by changes in systemic blood pressure.
In patient s with a normal serum sodium concentra-
tion (2:137 mmol/liter ), creatin ine clearance increased
with captopril (+21%, p < 0.05), but not with enalapril
( - 6%, P = NS). In contrast, in hyponatremic patients,
creatinine clearance did not change significantly with
captopril ( - 13%, P =NS), but decreased with enalapril
( - 24%, P < 0.05). In addition, patients who were di-
abetic and who received large doses of furosemide (> 80
mg daily) showed a decrease in creatinine clearance only
if they were also hyponatremic, but not if they had a
normal pretreatment serum sodium concentration.
These findings indicate that hyponatremic patients
with heart failure are not only at risk of symptomatic
hypotension, but are likely to develop functional renal
insufficiency during treatment with converting enzyme
inhibitors.
(J Am Coli Cardiol 1987;10:837-44)
peeted consequences of interfe rence with the renin -angi-
otensi n system , which evo lved to prese rve systemic blood
press ure and renal funct ion in low output states (5). As
cardiac output and renal blood flow dec line , renin is released
from the kidney: the result ing increase in angiotensin II acts
to support systemic perfusion and glomerular filtration pres-
sures by systemic arteriolar and intrarenal efferent arter iolar
vasoco nstriction, respecti vely (6-9) , Consequently, when
the act ions of angiotensin II are suppresse d, systemic and
intrag lomerular pressures may decl ine markedl y (9); this
leads to symptomatic hypotension and worsening rena l func-
tion in 20 to 50% of patient s with heart fa ilure treated with
captopri J or cnalapril (3,5 ,10-12) .
Identificat ion of patient s with heart failure at risk of
symptomatic hypoten sion and functional renal insufficiency
after converting enzyme inhibi tion is an important goa l.
0735-10<J7/87/$3.5ll
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Once accomplished, such patients can be carefully observed
during short- and long-term treatment with these drugs, so
that measures to reverse or prevent these adverse cardiorenal
effects can be instituted promptly. We might expect patients
with the most marked activation of the renin-angiotensin
system to be at greatest risk of these adverse cardiorenal
events (10); such marked neurohormonal activation can be
identified clinically by the measurement of serum sodium
concentration, which provides an accurate estimate of an-
giotensin dependence (10,13,14). In a previous report (10),
we showed that patients with hyponatremic heart failure
were at risk of symptomatic hypotension during initiation
of converting enzyme inhibition. In the present study, we
extend these earlier observations to show that such patients
are also at risk of functional renal insufficiency during treat-
ment with captopril and enalapril.
Methods
Study patients. We studied 67 patients with severe chronic
heart failure in whom creatinine clearance was measured
before and during long-term treatment with captopril or
enalapril. Of these 67 patients, 8 were excluded from the
present analysis because they had either bilateral renal artery
stenosis or severe renal insufficiency (creatinine clearance
< 10 mllmin). All of the remaining 59 patients had dyspnea
or fatigue at rest or on minimal exertion despite optimal
therapy with digitalis and diuretic drugs. There were 48 men
and II women, aged 28 to 80 years (mean 63). The cause
of heart failure was ischemic heart disease in 38 patients,
primary dilated cardiomyopathy in 18 patients, and primary
aortic valvular regurgitation in 3 patients. All patients had
a left ventricular ejection fraction <35%. All patients had
been clinically stable for at least 2 weeks before entry into
the study.
Study design. Before the study, patients were stabilized
on a salt-restricted (2 g) diet while receiving constant doses
of digitalis and diuretic drugs; all previous vasodilator drugs
were discontinued for at least 5 days. Right heart catheter-
ization and arterial cannulation were then performed to mea-
sure intracardiac and systemic pressures, respectively (15).
Left ventricular filling pressure was estimated by the mean
pulmonary capillary wedge pressure or by the pulmonary
artery diastolic pressure after its identity with wedge pres-
sure was established. Thermodilution cardiac output was
determined in triplicate by a bedside cardiac output com-
puter using iced injectate. Within 24 hours after intravas-
cular instrumentation, blood samples were collected for de-
termination of blood urea nitrogen, serum creatinine and
sodium concentration and plasma renin activity. Endoge-
nous creatinine clearance (which was used as an index of
glomerular filtration rate) was measured in all patients, using
24 hour urine specimens collected immediately before right
heart catheterization.
Each patient then received long-term treatment with cap-
topril or enalapril for I to 3 months. The initial dose of
converting-enzyme inhibitor was 25 mg of captopril orally,
followed by long-term therapy with either captopril (75 to
450 mg orally daily; mean 218) or enalapril (20 to 40 mg
orally daily; mean 38). These large, fixed doses used were
based on protocols that were in progress at the time each
patient was evaluated for treatment (10,12); 34 of the 59
patients in this study were included in a previous report
(12). During the I to 3 month treatment period, doses of
digitalis, diuretic drugs and the converting enzyme inhibitor
remained unaltered and a salt-restricted (2 g) diet was main-
tained. At the end of the treatment period, patients were
again hospitalized for a brief stabilization period, during
which time each patient underwent repeat determinations of
blood urea nitrogen, serum creatinine and sodium concen-
trations and endogenous creatinine clearance, using pro-
cedures identical to those used during the pretreatment eval-
uation.
Data analysis. Patients were divided into two groups
on the basis of changes in creatinine clearance observed
during the course of converting enzyme inhibition in the
present study. In 33 of the 59 patients, creatinine clearance
increased or remained constant « 10% change) during treat-
ment with captopril or enalapril (Group I), whereas the
remaining 26 patients experienced worsening renal function
(Group II), as manifested by a > 10% decline in creatinine
clearance. Qualitative and quantitative differences in pre-
treatment variables between the two groups were evaluated
by the t test for independent variables and the chi-square
statistic (using Yates' correction for continuity), respec-
tively. Quantitative differences among multiple subgroups
were evaluated by analysis of variance. Delineation of pre-
treatment variables that independently predicted the devel-
opment of functional renal insufficiency was achieved by
stepwise logistic regression analysis. Group data are ex-
pressed as mean ± standard error of the mean.
Results
By definition, creatinine clearance increased in Group I
(43.5 ± 3.3 to 54.3 ± 4.1 mllmin) and decreased in Group
II (50.3 ± 4.2 to 32.7 ± 3.3 mllmin) during treatment
with captopril and enalapril. These changes in renal function
were not related to differences in the magnitude of the hy-
potensive response to converting enzyme inhibition because
the decrease in mean arterial pressure at peak drug effect
during long-term therapy in Groups I and II was similar
(- 16.9 and - 16.2 mm Hg, respectively).
Identification of patients at risk of worsening renal
function. The 33 patients in Group I and the 26 patients
in Group II were similar with respect to age, sex, cause of
heart failure, history of hypertension, pretreatment renal
function and all pretreatment hemodynamic variables (Table
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Table 1. Pretreatment Clinical, Biochemical and Hemodynamic Variables in 59 Patients
Grouped According to Changes in Renal Function During Converting Enzyme Inhibition
Group I
(n = 33)
Group II
(n = 26)
p
Value
Age (yr)
Sex (men/women)
Cause of heart failure
History of systemic hypertension (no.)
Diabetes mellitus (no.)
% Patients treated with enalapril
Captopril dose (rug/day)
Enalapril dose (rug/day)
Furosemide dose (mg/day)
Serum sodium concentration (rnmol/liter)
Plasma renin activity (ng/ml per h)
Blood urea nitrogen (mg/dl)
Serum creatinine (rng/dl)
Creatinine clearance (ml/min)
Body weight (kg)
Cardiac index (liters/min per nr')
Mean arterial pressure (mm Hg)
LV filling pressure (mm Hg:
Mean right atrial pressure (mm Hg)
Heart rate (beats/min)
Systemic vascular resistance (dynes . s . ern ')
64.0:+: 2.2
2617
ICM 22. POC 10. VR I
10/33 (30%)
5133 (15(!c)
7133 (21'ii)
217 + 17
37 + 3
84 ± 6
137.0 ± n.6
3.n :+: 0.5
33.0 :' 3.6
J.5 :+: 0.2
43.5 ± 3.3
66.6 ± 2.5
171 + .08
82.X + 2.5
26.3 ± O.lI
III ± 1.1
80.4 :+: 2.6
2.056 ± 132
60.7 :+: 27
22/4
lCM 16. POC 8. VR 2
6/26 (23%)
11/26 (42%)
13/26 (50')'r)
2111 ± 22
38 ± 2
108 ± II
134.8 ± 1.0
10.6 :+: 3.4
2l1.8 ± 2.5
1.4 :+: 0.1
50.3 :+: 4.2
66.2 :+: 3.1
1.75 :+: .07
7l1.8 :+: 2.3
26.2 :+: 1.0
11.0 ± 1.0
84.5 ± 2.6
1.937 ± 117
NS
NS
NS
NS
<0.05
<0.05
NS
NS
«l.05
<0.05
<0.02
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
lCM = ischemic cardiomyopathy; LV = left ventricular; Na = sodium; NS = not significant; POC =
primary dilated cardiomyopathy; VR = primary valvular regurgitation.
enzyme inhibition (47.6 ± 4.2 to 34.5 ± 3.4 ml/min, p
< 0.001); in contrast, we observed no notable change in
creatinine clearance in patients with lower renin values (p
< 0.001 between the two groups) (Fig. I). Similarly, when
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Figure 1. Changes in creatinine clearance during long-term con-
verting enzyme inhibition in patients with severe chronic heart
failure grouped according to pretreatment values for serum sodium
concentration and plasma renin activity. Control (pretreatment)
values are designated in the open bars; posttreatment values arc
shown inthehatched bars. Thenumber of patients ineach subgroup
is shown at the bottom of each pair of bars. Data are expressed
as mean ± SEM. *p < 0.001; :j:p < 0.05.
I). Patients in Group II, however, had lower values for
serum sodium concentration (134.8 ± 1.0 versus 137.0 ±
0.6 mmol/liter, p < 0.05), higher values for plasma renin
activity (10.6 ± 3.4 versus 3.0 ± 0.5 ng/ml per hour, p
< 0.02) and received larger doses of furosemide (108 ±
II versus 84 ± 6 mg/day, p < 0.05) than did patients in
Group I. In addition, the percent of patients with diabetes
mellitus was greater in Group II than in Group I (42 versus
15%), as was that of patients treated with enalapril (50%
of Group II patients versus 21 % of Group I patients) (both
p < 0.(5).
By stepwise logistic regression analysis, only two vari-
ables-an elevated plasma renin activity and therapy with
enalapril-independently predicted a decrease in creatinine
clearance in these patients with severe heart failure. When
plasma renin activity was removed from the analysis, serum
sodium concentration (followed by enalapril therapy) emerged
as the most powerful independent predictor of changes in
renal function in the present study. The ability of serum
sodium concentration to predict changes in renal function
was attributable to its ability to reflect the degree of acti-
vation of the renin-angiotensin system, since values for serum
sodium concentration varied linearly and inversely with val-
ues for plasma renin activity (r = ~O.67).
When patients were separated into two groups on the
basis ofa pretreatment plasma renin activitv oj'S nglml per
h, only patients with a plasma renin activity 2:5 ng/rnl per
h showed a decrease in creatinine clearance after converting
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Figure 3. Changes in creatinine clearance during long-term con-
verting-enzyme inhibition in patients with severe chronic heart
failure separated into four groups on the basis of pretreatment
values for serum sodium (Na) concentration and the presence (OM)
or absence (NOM) of diabetes mellitus. Format as in Figure I. +p
< 0.05.
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and diabetes mellitus as riskfactorsfor worsening azotemia.
we noted little change in creatinine clearance in patients
with heart failure with a normal serum sodium concentra-
tion, whether or not they had diabetes mellitus (+ 10% in
both groups, both p = NS). In contrast, in patients with
hyponatremic heart failure, creatinine clearance was not
significantly altered by convertingenzyme inhibitionin non-
diabetic patients (- 14%, P = NS), but declined signifi-
cantly in diabetic patients ( - 24%, P < 0.02) (Fig. 3).
When we analyzed the interaction between serum sodium
concentration and the dose of diuretics as risk factors for
patients were separated into two groups based on pretreat-
ment serum sodium concentration, only patients with hy-
ponatremia (serum sodium> 137 mmollliter) showed a de-
crease in creatinine clearance with captopril and enalapril
(46.6 ± 3.9 to 38.9 ± 3.3 mllmin, p < 0.05), whereas
renal function remained unaltered in patients with a normal
pretreatment serum sodium concentration (serum sodium
~ 137 mrnol/liter), (p < 0.00 I between the two groups)
(Fig. I). The deterioration in renal function in hyponatremic
patients and patients with elevated values for plasma renin
activity was not related to a more profound hypotensive
response to long-term treatment in these patients, since the
decline in mean arterial pressure at peak drug effect after I
to 3 months of therapy did notdifferamong the foursubgroups
(10,16).
Interaction of hyponatremia and other risk factors.
A significant interaction was noted between serum sodium
concentration and the type of converting enzyme inhibitor
in determining changes in renal function during this study
(Fig. 2). In patients with a normal serum sodium concen-
tration, creatinine clearance increased significantly during
treatment with captopril (+ 21%, P < 0.05), but not during
treatment with enalapril ( - 6%, P = NS). In contrast, in
patients with hyponatremia, creatinine clearance did not
change significantly with captopril ( - 13%, P = NS), but
decreased significantly with enalapril ( - 24%, P < 0.05).
The risk of worsening renal function in captopril-treated
patients with hyponatremia was similar to that of enalapril-
treated patients with a normal serum sodium concentration.
These observationsconfirmthat hyponatremia and enalapril
therapy were independent risk factors for the development
of renal insufficiency in our patients.
When we analyzed the interaction between hyponatremia
Figure 4. Changes in creatinine clearance during long-term con-
verting-enzyme inhibition in patients with severe chronic heart
failure separated into four groups on the basis of pretreatment
values for serum sodium (Na) concentration and the dose of fu-
rosemide used in the study. Format as in Figure I. +p < 0.01.
Figure 2. Changes in creatinine clearance during long-term con-
verting enzyme inhibition in patients with severe chronic heart
failure separated into four groups on the basis of pretreatment
values for serum sodium (Na) concentration and the specific con-
verting-enzyme inhibitor used during the study. CPT = captopril;
ENL = enalapril; format as in Figure I. +p < 0.05. SERUM No~137mmol/1 SERUM No < 137 mmol/1
SERUM No~ [37 mmol/l SERUM No < 137mmol/l 75
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f unctional renal insufficiency. patients with a normal serum
sodium concentration showed little change in creatinine
clearance, regardless of whether they received small doses
(less than or equal to the median value of 80 mg daily) or
large doses of furosemide (+ II and + 6%, respectively,
both p = NS) (Fig. 4). In contrast, in patients with hy-
ponatremia, creatinine clearance was not altered by con-
verting enzyme inhibition in those treated with small doses
of furosemide ( - 1%, P = NS), but decreased substantially
in the hyponatremic patients treated with large doses of
diuretic drugs ( - 36%, P < 0.01).
Discussion
In states of compromised renal perfusion, glomerular
function is preserved by efferent arteriolar vasoconstriction,
which acts to increase glomerular hydraulic pressures and
glomerular filtration rate (8,9). The importance of this com-
pensatory response is exaggerated when renal perfusion
pressure is markedly reduced or when sodium stores are
depleted (8, 17-2 1), both of which serve to stimulate the
intrarenal production of angiotensin II, which in turn acts
to preserve glomerular function by its constrictor actions on
the efferent arteriole (19-2 1). Unfortunately, when released
systemically, angiotensin II also causes systemic vasocon-
striction, which leads to a deterioration in cardiac perform-
ance in the patient with heart failure (22) . Consequently,
attempts to preserve cardiac function by converting enzyme
inhibition may improve ventricular performance. but at the
risk of antagonizing the beneficial intrarenal actions of an-
giotensin II, thus causing a deterioration in renal function
(4 ,5 ).
Risk factors predisposing to drug-induced functional
renal insufficiency. Who is at risk of functional renal in-
sufficiency after the withdrawal of the intrarenal actions of
the renin-angiotensin system? Previous experimental and
clinical observations have suggested that three physiologic
conditions must be met to create the specific conditions by
which renal function is dependent on angiotensin II. First.
subjects must be sodium-depleted (8, 11 ,17.21); this concept
is supported by the observations of the present study in
which patients whose renal function deteriorated (Group II)
were treated with larger doses of furosemide than were
patients in whom renal function was preserved (Group I).
Second, the renin-angiotensin system must be markedly ac-
tivated (8,12,23,24); accordingly, patients who developed
worsening azotemia in our study had higher values for plasma
renin activity than did patients whose renal function re-
mained unaltered. Third, renal perfusion must be severely
compromised; when renal artery pressure is very low, ef-
ferent arteriolar vasoconstriction is critical to maintenance
of intraglomerular hydraulic pressures (8, 17, 20). Yet, in
the present study, pretreatmentvalues for mean arterial pres-
sure were not notably lower in patients in Group II than in
patients in Group I; pretreatment values for systemic blood
pressure did not presage subsequent changes in renal func-
tion.
Could alternative measures of renal perfusion (such as
the direct measurement of renal blood flow rather than renal
perfusion pressure) have been able to distinguish between
our two patient subgroups? We do not know, since such
assessments were not performed in this study.
Hyponatremia as an index of compromised renal per-
fusion in heart failure. How then can we determine which
patients with congestive heart failure have the most com-
promised renal perfusion and, thus, would be expected to
be at greatest risk of functional renal insufficiency after
converting enzyme inhibition? Recent evidence (25,26) sug-
gests that the presence of hyponatremia identifies patients
with congestive heart failure, in whom end-organ blood flow
(particularly to the kidneys) is critically reduced. Whereas
patients with a normal serum sodium concentration are clin-
ically well compensated and respond normally to circulatory
stress (25-27), patients with hyponatremia are clinically
decompensated (26), have elevated levels of stress hor-
mones (27) , commonly show prerenal azotemia and abnor-
mal liver function tests (14.27,28) and have a reduced ability
to react to interventions that further reduce cardiac output
(25). The normal homeostatic mechanisms that maintain
peripheral perfusion in congestive heart failure have been
exhausted in hyponatremic patients: instead, end-organ per-
fusion and function is maintained by activation of neuro-
hormonal forces. particularly the renin-angiotensin system.
This shift from normal to deranged homeostatic control rep-
resents a critical milestone in the progressive deterioration
of patients with congestive heart failure to terminal left
ventricular dysfunction and death; once reached, morbidity
and mortality are greatly accelerated (14). Unfortunately,
conventional measures of left ventricular function are not
sufficiently sensitive to detect this critical circulatory shift:
at present, it can only be appreciated by the direct mea-
surement of regional blood flow or by the assessment of the
reactive neurohormonal response to peripheral hypoperfu-
sion, a task most easily accomplished by the measurement
of serum sodium concentration (28).
The findings of the present study strongly support the
concepts outlined above. Patients whose renal function de-
teriorated after converting-enzyme inhibition had signifi -
cantly lower pretreatment values for serum sodium concen-
tration than did patients whose renal function was preserved.
When plasma renin activity is excluded from the analysis
(because it is not immediately available to most clinicians
at the time that therapy with converting enzyme inhibitors
is instituted). hyponatremia was the most important predic-
tor of the development of functional renal insufficiency in
our patient cohort. Although renal blood flow in hypona-
tremic patients is markedly impaired (25), glomerular fil-
tration rate (in the present study) was similar to that seen
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in patients with a normal serum sodium concentration (14).
This observation suggests that filtration fraction is markedly
increased in hyponatremic heart failure, most probably the
result of efferent arteriolar vasoconstriction that follows the
marked activation of the renin-angiotensin system in these
patients (8). Hence, glomerular filtration rate in hypona-
tremic heart failure is angiotensin Il-dependent; conse-
quently, these patients are at greatest risk of worsening renal
function after interventions that suppress the formation of
angiotensin II (24).
Interaction of hyponatremia and other risk factors.
The presence of compromised renal perfusion in the present
study (as indicated by the finding of hyponatremia) was a
necessary but not sufficient factor predisposing to the de-
velopment of functional renal insufficiency in our patients
with heart failure treated with converting enzyme inhibitors
(24); this conclusion was derived from clinical data and is
similar to that reached from observations made in experi-
mental low output states (8,17-21). Specifically, we ob-
served no decrease in creatinine clearance in hyponatremic
patients unless they also had diabetes mellitus (29), received
high doses of furosemide (II) or were treated with the long-
acting converting enzyme inhibitor enalapril (12); all three
factors are capable of compromising the integrity of the
compensatory efferent arteriolar vasoconstrictor response to
a decrease in renal perfusion. Glomerular vascular respon-
siveness to angiotensin II is dependent on the action of
insulin (30,31) and, thus, efferent arteriolar vasoconstriction
is defective in patients with diabetes mellitus, thereby pre-
disposing these patients to the development of worsening
azotemia after converting enzyme inhibition (29,32). Sim-
ilarly, the degree of dependence of efferent arteriolar func-
tion on angiotensin II is determined by sodium balance
(8,17) and is greatly exaggerated in sodium-depleted states.
Consequently, functional renal insufficiency can be pro-
voked by interventions that reduce intravascular volume,
and may be ameliorated by the withdrawal of potent diuretic
therapy (II).
Finally, because the continuous suppression of angioten-
sin II formation might be expected to produce more sus-
tained hypotensive effects and compromise efferent arte-
riolar vasoconstriction more than intermittent interruption of
the renin-angiotensin system (5), the risk of functional renal
insufficiency is greater in patients treated with a long-acting
converting enzyme inhibitor than in those treated with a
short-acting agent (12). In fact, therapy with enalapril was
the only variable (after the measurement of serum sodium
concentration) that provided independent information re-
garding the risk of renal insufficiency. This risk of long-
acting converting enzyme inhibitors in patients with severe
chronic heart failure has recently been confirmed in a dou-
ble-blind multicenter comparative study (33) of captopril
and lisinopril (an investigational long-acting converting en-
zyme inhibitor), in which the frequency of worsening azo-
temia was significantly greater in the lisinopril-treated group
than in the captopril-treated group (18 versus 5%).
Role of administered dose of captopril and enalapril.
Our data do not support the concept that the dose of con-
verting enzyme inhibitor administered for the treatment of
congestive heart failure is an important determinant of func-
tional renal insufficiency in these patients (34), since the
doses of captopril and enalapril used in patients in Groups
I and II were similar. When administered in the usual ther-
apeutic doses, converting enzyme inhibitors generally dem-
onstrate a relatively flat dose-response curve (35,36). Hence,
although the doses of both captopril and enalapril used in
this study were high, such doses do not produce greater
degrees of systemic hypotension or greater inhibition of
angiotensin-mediated efferent arteriolar vasoconstriction than
do substantially smaller doses of these drugs (35-37). Since
these two hemodynamic events are critical in the pathogen-
esis of worsening renal function, we would not expect low
doses of converting enzyme inhibitors to produce less renal
insufficiency than high doses. Only very low doses of these
drugs (6.25 mg of captopril and 2.5 mg of enalapril) appear
capable of producing less than maximal hypotensive effects
"'(35,36), but there is little evidence that such small doses
are effective in the treatment of congestive heart failure,
and they may still produce a serious deterioration in renal
function (38). Recent evidence (1 I) suggests that a reduction
in the dose of concomitantly administered diuretics may be
a more effective approach to the management of functional
renal insufficiency in patients with chronic heart failure than
would a reduction in the dose of the converting enzyme
inhibitor. Even such an approach, however, may not com-
pletely ameliorate the problem of worsening azotemia in
high risk patients (33,38).
Role of renin-angiotensin system. Although our data in-
dicate that the renin-angiotensin system plays an important
role in preserving renal function in states of compromised
renal perfusion (24), this hormonal system may exert dif-
ferent physiologic effects under different pathologic states.
Angiotensin II not only exerts direct vasoconstrictor actions
on the efferent arteriole (which serve to increase the glo-
merular filtration rate), but also acts on the glomerular mes-
angial cell to reduce the ultrafiltration coefficient (39,40)
(which serves to decrease the glomerular filtration rate). The
net effect of converting enzyme inhibitors on renal function,
therefore, is highly dependent on the physiologic conditions
that are present before and during treatment with captopril
and enalapril. In hyponatremic patients (in whom pretreat-
ment renal perfusion is compromised), efferent arteriolar
vasoconstriction appears to be the dominant site of angi-
otensin II action (8,17) and, thus, creatinine clearance de-
clines after converting enzyme inhibition, especially if renal
perfusion is further compromised by continuous drug-in-
duced hypotension. Conversely, in patients with a normal
serum sodium concentration (in whom renal perfusion is
lACC Vol. 10, No, 4
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relatively preserved), the glomerular mesangium may emerge
as the dominant site of angiotensin II action and, thus,
glomerular filtration rate may increase after converting en-
zyme inhibition(as we noted during therapy with captopril)
(9), Such a benefit may not be observed, however, if it is
offset by a persistent decrease in renal perfusion pressure,
as might be seen after continuous drug-induced systemic
hypotension (as during therapy with enalapril) (12),
Conclusion. Hyponatremia is an important risk factor
for the development of functional renal insufficiency during
converting enzyme inhibitionin patientswith severechronic
heart failure, Although such patients demonstrate an ad-
vanced degree of circulatory failure, which is characterized
by profoundly impairedend organ perfusion, they generally
show relative preservation of end organ (especially renal)
function as a result of activation of the renin-angiotensin
system, Consequently, when a convertingenzyme inhibitor
is administered in an effort to improvecardiac performance,
hyponatremic patients are likely to experience a deteriora-
tion in renal function, especially when physiologic or patho-
logic conditions coexist that modify the intrarenal micro-
circulatory response to circulatory stress (diabetes mellitus,
diuretic drugs and long-acting converting enzyme inhibi-
tors). Since such patients are also at high risk of sympto-
matic hypotension during initiation of converting enzyme
inhibition (10), these individuals merit special attention when
this therapeutic approach is being considered for the treat-
ment of congestive heart failure.
We are indebted to the nurses, cardiology fellows and staff of the Ames
and Rose Cardiac Care Units of the Mount Sinai Hospital for the excellent
care that they provided for the patients in this study,
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